Substituted phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonamides as antimitotics. Antiproliferative, antiangiogenic and antitumoral activity, and quantitative structure-activity relationships

European Journal of Medicinal Chemistry

Volumn 46, Issue 11, 2011, Pages 5327-5342

  Fortin, Sébastien ^a,b   Wei, Lianhu ^c   Moreau, Emmanuel ^d   Lacroix, Jacques ^a   Côté, Marie France ^a   Petitclerc, Éric ^a,f   Kotra, Lakshmi P ^c,e   Gaudreault, René C ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITÉ CLERMONT AUVERGNE   (France)

^e UNIVERSITY OF TORONTO   (Canada)

^f HÉMA QUÉBEC   (Canada)

Author keywords

Anticancer drugs; Antimicrotubule agents; Antimitotic agents; Phenyl 4 (2 oxoimidazolidin 1 yl)benzenesulfonamides; PIB SA

Indexed keywords

ANTIMITOTIC AGENT; BENZENESULFONAMIDE DERIVATIVE; N (2 ETHYLPHENYL) 4 (2 OXOIMIDAZOLIDIN 1 YL)BENZENESULFONAMIDE; N (2 METHOXYPHENYL) 4 (2 OXOIMIDAZOLIDIN 1 YL)BENZENESULFONAMIDE; N (2,3 DIMETHYLPHENYL) 4 (2 OXOIMIDAZOLIDIN 1 YL)BENZENESULFONAMIDE; N (2,4 DIMETHYLPHENYL) 4 (2 OXOIMIDAZOLIDIN 1 YL)BENZENESULFONAMIDE; N (2,5 DIMETHYLPHENYL) 4 (2 OXOIMIDAZOLIDIN 1 YL)BENZENESULFONAMIDE; N (3 BROMOPHENYL) 4 (2 OXOIMIDAZOLIDIN 1 YL)BENZENESULFONAMIDE; N (3 CHLOROPHENYL) 4 (2 OXOIMIDAZOLIDIN 1 YL)BENZENESULFONAMIDE; N (3 ETHYLPHENYL) 4 (2 OXOIMIDAZOLIDIN 1 YL)BENZENESULFONAMIDE; N (3 METHOXYPHENYL) 4 (2 OXOIMIDAZOLIDIN 1 YL)BENZENESULFONAMIDE; N (3 PHENOXYPHENYL) 4 (2 OXOIMIDAZOLIDIN 1 YL)BENZENESULFONAMIDE; N (3,4 DIFLUOROPHENYL) 4 (2 OXOIMIDAZOLIDIN 1 YL)BENZENESULFONAMIDE; N (3,4 DIMETHOXYPHENYL) 4 (2 OXOIMIDAZOLIDIN 1 YL)BENZENESULFONAMIDE; N (3,4 DIMETHYLPHENYL) 4 (2 OXOIMIDAZOLIDIN 1 YL)BENZENESULFONAMIDE; N (3,4,5 TRIMETHOXYPHENYL) 4 (2 OXOIMIDAZOLIDIN 1 YL)BENZENESULFONAMIDE; N (3,5 DI TERT BUTYLPHENYL) 4 (2 OXOIMIDAZOLIDIN 1 YL)BENZENESULFONAMIDE; N (3,5 DIMETHOXYPHENYL) 4 (2 OXOIMIDAZOLIDIN 1 YL)BENZENESULFONAMIDE; N (3,5 DIMETHYLPHENYL) 4 (2 OXOIMIDAZOLIDIN 1 YL)BENZENESULFONAMIDE; N (4 BUTYLPHENYL) 4 (2 OXOIMIDAZOLIDIN 1 YL)BENZENESULFONAMIDE; N (4 ETHYLPHENYL) 4 (2 OXOIMIDAZOLIDIN 1 YL)BENZENESULFONAMIDE; N (4 SEC BUTYLPHENYL) 4 (2 OXOIMIDAZOLIDIN 1 YL)BENZENESULFONAMIDE; N (4 TERT BUTYLPHENYL) 4 (2 OXOIMIDAZOLIDIN 1 YL)BENZENESULFONAMIDE; N 2 TOLYL 4 (2 OXOIMIDAZOLIDIN 1 YL)BENZENESULFONAMIDE; N 3 TOLYL 4 (2 OXOIMIDAZOLIDIN 1 YL)BENZENESULFONAMIDE; N 4 TOLYL 4 (2 OXOIMIDAZOLIDIN 1 YL)BENZENESULFONAMIDE; N PHENYL 4 (2 OXOIMIDAZOLIDIN 1 YL)BENZENESULFONAMIDE; SULFONAMIDE; SULFONIC ACID DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL STRAIN MCF 7; CHORIOALLANTOIS; COLON CARCINOMA; FIBROSARCOMA; HUMAN; HUMAN CELL; MELANOMA;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIMITOTIC AGENTS; BINDING SITES; CELL LINE, TUMOR; CELL PROLIFERATION; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; COLCHICINE; HUMANS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80054895057     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2011.08.034     Document Type: Article

References (58)

1. American Cancer Society Cancer Facts & Figures 2010 American Cancer Society Atlanta 2010
2. International Agency for Research on Cancer World Cancer Report 2008 World Health Organization
3. Organisation mondiale de la Santé et Union Internationale Contre le Cancer Action Mondiale Contre le Cancer URL 2005 accessed 26 04 11
4. J.K. Buolamwini Novel anticancer drug discovery Curr. Opin. Chem. Biol. 3 1999 500 509 (Pubitemid 29376114)
5. M.A. Jordan, and L. Wilson Microtubules as a target for anticancer drugs Nat. Rev. Cancer 4 2004 253 265 (Pubitemid 38525281)
6. P.M. Checchi, J.H. Nettles, J. Zhou, J.P. Snyder, and H.C. Joshi Microtubule-interacting drugs for cancer treatment Trends Pharmacol. Sci. 24 2003 361 365 (Pubitemid 37315528)
7. G. Attard, A. Greystoke, S. Kaye, and J. De Bono Update on tubulin-binding agents Pathol. Biol. (Paris) 54 2006 72 84
8. G.K. Chen, G.E. Duran, A. Mangili, L. Beketic-Oreskovic, and B.I. Sikic MDR 1 activation is the predominant resistance mechanism selected by vinblastine in MES-SA cells Brit. J. Cancer 83 2000 892 898
9. C. Dumontet, G.E. Duran, K.A. Steger, L. Beketic-Oreskovic, and B.I. Sikic Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol) Cancer Res. 56 1996 1091 1097 (Pubitemid 26065405)
10. D.M. Patterson, and G.J. Rustin Vascular damaging agents Clin. Oncol. (R. Coll. Radiol.) 19 2007 443 456 (Pubitemid 46995617)
11. C. Kanthou, and G.M. Tozer Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies Int. J. Exp. Pathol. 90 2009 284 294
12. N.H. Nam Combretastatin A-4 analogues as antimitotic antitumor agents Curr. Med. Chem. 10 2003 1697 1722
13. J.M. Dziba, R. Marcinek, G. Venkataraman, J.A. Robinson, and K.B. Ain Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors Thyroid 12 2002 1063 1070 (Pubitemid 36114813)
14. H.L. Anderson, J.T. Yap, M.P. Miller, A. Robbins, T. Jones, and P.M. Price Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate J. Clin. Oncol. 21 2003 2823 2830 (Pubitemid 46621829)
15. D. Simoni, R. Romagnoli, R. Baruchello, R. Rondanin, M. Rizzi, M.G. Pavani, D. Alloatti, G. Giannini, M. Marcellini, T. Riccioni, M. Castorina, M.B. Guglielmi, F. Bucci, P. Carminati, and C. Pisano Novel combretastatin analogues endowed with antitumor activity J. Med. Chem. 49 2006 3143 3152 (Pubitemid 43830513)
16. J.P. Stevenson, M. Rosen, W. Sun, M. Gallagher, D.G. Haller, D. Vaughn, B. Giantonio, R. Zimmer, W.P. Petros, M. Stratford, D. Chaplin, S.L. Young, M. Schnall, and P.J. O'Dwyer Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow J. Clin. Oncol. 21 2003 4428 4438 (Pubitemid 46621821)
17. S. Aprile, E. Del Grosso, G.C. Tron, and G. Grosa In vitro metabolism study of combretastatin A-4 in rat and human liver microsomes Drug Metab. Dispos. 35 2007 2252 2261 (Pubitemid 350146212)
18. S.L. Young, and D.J. Chaplin Combretastatin A4 phosphate: background and current clinical status Expert Opin. Inv. Drug 13 2004 1171 1182 (Pubitemid 39242740)
19. S. Fortin, L. Wei, E. Moreau, J. Lacroix, M.-F. Côté, É. Petitclerc, L.P. Kotra, and R.C. Gaudreault Design, synthesis, biological evaluation and structure-activity relationships of substituted phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonates as new tubulin inhibitors mimicking combretastatin A-4 J. Med. Chem. 54 2011 4559 4580
20. G.C. Tron, T. Pirali, G. Sorba, F. Pagliai, S. Busacca, and A.A. Genazzani Medicinal chemistry of combretastatin A4: present and future directions J. Med. Chem. 49 2006 3033 3044 (Pubitemid 43830499)
21. C.T. Supuran, A. Casini, and A. Scozzafava Protease inhibitors of the sulfonamide type: anticancer, antiinflammatory, and antiviral agents Med. Res. Rev. 23 2003 535 558 (Pubitemid 37034144)
22. A. Casini, A. Scozzafava, and C.T. Supuran Sulfonamide derivatives with protease inhibitory action as anticancer, antiinflammatory and antiviral agents Exp. Opin. Ther. Pat 12 2002 1307 1327
23. K.M. Neff, and J.J. Nawarskas Hydrochlorothiazide versus chlorthalidone in the management of hypertension Cardiol. Rev. 18 2010 51 56
24. M.H. Parker, V.L. Smith-Swintosky, D.F. McComsey, Y. Huang, D. Brenneman, B. Klein, E. Malatynska, H.S. White, M.E. Milewski, M. Herb, M.F. Finley, Y. Liu, M.L. Lubin, N. Qin, R. Iannucci, L. Leclercq, F. Cuyckens, A.B. Reitz, and B.E. Maryanoff Novel, broad-spectrum anticonvulsants containing a sulfamide group: advancement of N-((benzo[b]thien-3-yl)methyl)sulfamide (JNJ-26990990) into human clinical studies J. Med. Chem. 52 2009 7528 7536
25. B.E. Maryanoff, S.O. Nortey, J.F. Gardocki, R.P. Shank, and S.P. Dodgson Anticonvulsant O-alkyl sulfamates. 2,3:4,5-bis-O-(1-methylethylidene)-beta-D- fructopyranose sulfamate and related compounds J. Med. Chem. 30 1987 880 887
26. C.T. Supuran, A. Scozzafava, and A. Casini Carbonic anhydrase inhibitors Med. Res. Rev. 23 2003 146 189 (Pubitemid 36241096)
27. C.T. Supuran, A. Casini, A. Mastrolorenzo, and A. Scozzafava COX-2 selective inhibitors, carbonic anhydrase inhibition and anticancer properties of sulfonamides belonging to this class of pharmacological agents Mini-Rev. Med. Chem. 4 2004 625 632 (Pubitemid 38961227)
28. A.E. Boyd 3rd, Sulfonylurea receptors, ion channels, and fruit flies Diabetes 37 1988 847 850
29. B. Shan, J.C. Medina, E. Santha, W.P. Frankmoelle, T.C. Chou, R.M. Learned, M.R. Narbut, D. Stott, P. Wu, J.C. Jaen, T. Rosen, P.B. Timmermans, and H. Beckmann Selective, covalent modification of β-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors Proc. Natl. Acad. Sci. U. S. A. 96 1999 5686 5691 (Pubitemid 29234679)
30. J.D. Berlin, A. Venook, E. Bergsland, M. Rothenberg, A.C. Lockhart, and L. Rosen Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma Clin. Colorectal Canc 7 2008 44 47 (Pubitemid 351252450)
31. S. Kirby, S.Z. Gertler, W. Mason, C. Watling, P. Forsyth, J. Aniagolu, R. Stagg, M. Wright, J. Powers, and E.A. Eisenhauer Phase 2 study of T138067-sodium in patients with malignant glioma: trial of the National cancer Institute of Canada clinical trials group Neuro-Oncology 7 2005 183 188 (Pubitemid 40590518)
32. K. Yoshimatsu, A. Yamaguchi, H. Yoshino, N. Koyanagi, and K. Kitoh Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin Cancer Res. 57 1997 3208 3213 (Pubitemid 27351737)
33. A.M. Mauer, E.E. Cohen, P.C. Ma, M.F. Kozloff, L. Schwartzberg, A.I. Coates, J. Qian, A.E. Hagey, and G.B. Gordon A phase II study of ABT-751 in patients with advanced non-small cell lung cancer J. Thorac. Oncol. 3 2008 631 636 (Pubitemid 351787308)
34. J. Michels, S.L. Ellard, L. Le, C. Kollmannsberger, N. Murray, E.S. Tomlinson Guns, R. Carr, and K.N. Chi A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer Ann. Oncol. 21 2010 305 311
35. K.W. Yee, A. Hagey, S. Verstovsek, J. Cortes, G. Garcia-Manero, S.M. O'Brien, S. Faderl, D. Thomas, W. Wierda, S. Kornblau, A. Ferrajoli, M. Albitar, E. McKeegan, D.R. Grimm, T. Mueller, R.R. Holley-Shanks, L. Sahelijo, G.B. Gordon, H.M. Kantarjian, and F.J. Giles Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies Clin. Cancer Res. 11 2005 6615 6624 (Pubitemid 41339002)
36. J.A. Segreti, J.S. Polakowski, K.A. Koch, K.C. Marsh, J.L. Bauch, S.H. Rosenberg, H.L. Sham, B.F. Cox, and G.A. Reinhart Tumor selective antivascular effects of the novel antimitotic compound ABT-751: an in vivo rat regional hemodynamic study Cancer Chemother. Pharmacol 54 2004 273 281 (Pubitemid 39141745)
37. J.P. Liou, K.S. Hsu, C.C. Kuo, C.Y. Chang, and J.Y. Chang A novel oral indoline-sulfonamide agent, N-[1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H- indol-7-yl]-isonicotinamide (J30), exhibits potent activity against human cancer cells in vitro and in vivo through the disruption of microtubule J. Pharmacol. Exp. Ther. 323 2007 398 405
38. J.Y. Chang, H.P. Hsieh, C.Y. Chang, K.S. Hsu, Y.F. Chiang, C.M. Chen, C.C. Kuo, and J.P. Liou 7-Aroyl-aminoindoline-1-sulfonamides as a novel class of potent antitubulin agents J. Med. Chem. 49 2006 6656 6659
39. C.G. Wermuth The Practice of Medicinal chemistry third ed. 2008 Elsevier/Academic Press Amsterdam, Boston
40. J. Nevillle, A.J. Lim, J.Su, D.-S.;R. Wood, M. MERCK & CO., Inc. Arylsulfonamide derivatives. Patent. International Application No. PCT/US2004/021018.
41. E.R. Parmee, E.M. Naylor, L. Perkins, V.J. Colandrea, H.O. Ok, M.R. Candelore, M.A. Cascieri, L. Deng, W.P. Feeney, M.J. Forrest, G.J. Hom, D.E. MacIntyre, R.R. Miller, R.A. Stearns, C.D. Strader, L. Tota, M.J. Wyvratt, M.H. Fisher, and A.E. Weber Human β3 adrenergic receptor agonists containing cyclic ureidobenzenesulfonamides Bioorg. Med. Chem. Lett. 9 1999 749 754 (Pubitemid 29130282)
42. National Cancer Institute (NCI/NIH), Developmental Therapeutics program Human Tumor Cell Line Screen, URL: , (accessed 02.2.11).
43. M.J. Schibler, and F. Cabral Taxol-dependent mutants of Chinese hamster ovary cells with alterations in α- and β-tubulin J. Cell Biol. 102 1986 1522 1531 (Pubitemid 16038095)
44. F. Cabral, M.E. Sobel, and M.M. Gottesman CHO mutants resistant to colchicine, colcemid or griseofulvin have an altered β-tubulin Cell 20 1980 29 36 (Pubitemid 10117297)
45. W.T. Beck, T.J. Mueller, and L.R. Tanzer Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemic lymphoblasts Cancer Res. 39 1979 2070 2076 (Pubitemid 9185002)
46. X.F. Hu, T.J. Martin, D.R. Bell, M. de Luise, and J.R. Zalcberg Combined use of cyclosporin A and verapamil in modulating multidrug resistance in human leukemia cell lines Cancer Res. 50 1990 2953 2957 (Pubitemid 20170744)
47. S. Fortin, J. Lacroix, M.-F. Côté, E. Moreau, E. Petitclerc, and R.C. Gaudreault Quick and simple detection technique to assess the binding of antimicrotubule agents to the colchicine-binding site BPO [Online] 12 2010 113 117 10.1007/s12575-010-9029-5
48. A.N. Jain Morphological similarity: a 3D molecular similarity method correlated with protein-ligand recognition J. Comput.-Aided Mol. Des 14 2000 199 213 (Pubitemid 30110675)
49. S. Struski, P. Cornillet-Lefebvre, M. Doco-Fenzy, J. Dufer, E. Ulrich, L. Masson, N. Michel, N. Gruson, and G. Potron Cytogenetic characterization of chromosomal rearrangement in a human vinblastine-resistant CEM cell line: use of comparative genomic hybridization and fluorescence in situ hybridization Cancer Genet. Cytogenet. 132 2002 51 54 (Pubitemid 34136051)
50. K. Ueda, C. Cardarelli, M.M. Gottesman, and I. Pastan Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine Proc. Natl. Acad. Sci. USA 84 1987 3004 3008 (Pubitemid 17064766)
51. E. Petitclerc, R.G. Deschesnes, M.F. Cote, C. Marquis, R. Janvier, J. Lacroix, E. Miot-Noirault, J. Legault, E. Mounetou, J.C. Madelmont, and R.C. Gaudreault Antiangiogenic and antitumoral activity of phenyl-3-(2-chloroethyl) ureas: a class of soft alkylating agents disrupting microtubules that are unaffected by cell adhesion-mediated drug resistance Cancer Res. 64 2004 4654 4663 (Pubitemid 38856940)
52. E. Petitclerc, A. Boutaud, A. Prestayko, J. Xu, Y. Sado, Y. Ninomiya, M.P. Sarras Jr., B.G. Hudson, and P.C. Brooks New functions for non-collagenous domains of human collagen type IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo J. Biol. Chem. 275 2000 8051 8061 (Pubitemid 30159718)
53. J. Kim, W. Yu, K. Kovalski, and L. Ossowski Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay Cell 94 1998 353 362 (Pubitemid 28376079)
54. T. Uchibayashi, S.W. Lee, K. Kunimi, M. Ohkawa, Y. Endo, M. Noguchi, and T. Sasaki Studies of effects of anticancer agents in combination with/without hyperthermia on metastasized human bladder cancer cells in chick embryos using the polymerase chain reaction technique Cancer Chemother. Pharmacol. 35 1994 S84 S87
55. P.C. Brooks, S. Silletti, T.L. von Schalscha, M. Friedlander, and D.A. Cheresh Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity Cell 92 1998 391 400 (Pubitemid 28093016)
56. U.K. Laemmli Cleavage of structural proteins during the assembly of the head of bacteriophage T4 Nature 227 1970 680 685
57. M.A. Lyu, Y.K. Choi, B.N. Park, B.J. Kim, I.K. Park, B.H. Hyun, and Y.H. Kook Over-expression of urokinase receptor in human epidermoid-carcinoma cell line (HEp3) increases tumorigenicity on chorio-allantoic membrane and in severe-combined-immunodeficient mice Int. J. Cancer 77 1998 257 263
58. SYBYL, 8.1, Tripos International, 1699 South Hanley Rd., St. Louis, Missouri, 63144, USA.